Cargando…

Development and validation of a new prognostic index for mortality risk in multimorbid adults

CONTEXT: Multimorbidity is highly prevalent among older adults and associated with a high mortality. Prediction of mortality in multimorbid people would be clinically useful but there is no mortality risk index designed for this population. Our objective was therefore to develop and internally valid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastens, Viktoria, Chiolero, Arnaud, Anker, Daniela, Schneider, Claudio, Feller, Martin, Bauer, Douglas C., Rodondi, Nicolas, Giovane, Cinzia Del
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355209/
https://www.ncbi.nlm.nih.gov/pubmed/35930547
http://dx.doi.org/10.1371/journal.pone.0271923
_version_ 1784763242905600000
author Gastens, Viktoria
Chiolero, Arnaud
Anker, Daniela
Schneider, Claudio
Feller, Martin
Bauer, Douglas C.
Rodondi, Nicolas
Giovane, Cinzia Del
author_facet Gastens, Viktoria
Chiolero, Arnaud
Anker, Daniela
Schneider, Claudio
Feller, Martin
Bauer, Douglas C.
Rodondi, Nicolas
Giovane, Cinzia Del
author_sort Gastens, Viktoria
collection PubMed
description CONTEXT: Multimorbidity is highly prevalent among older adults and associated with a high mortality. Prediction of mortality in multimorbid people would be clinically useful but there is no mortality risk index designed for this population. Our objective was therefore to develop and internally validate a 1-year mortality prognostic index for older multimorbid adults. METHODS: We analysed data of the OPERAM cohort study in Bern, Switzerland, including 822 adults aged 70 years or more with multimorbidity (3 or more chronic medical conditions) and polypharmacy (use of 5 drugs or more for >30 days). Time to all-cause mortality was assessed up to 1 year of follow-up. We performed a parametric Weibull regression model with backward stepwise selection to identify mortality risk predictors. The model was internally validated and optimism corrected using bootstrapping techniques. We derived a point-based risk score from the regression coefficients. Calibration and discrimination were assessed by the calibration slope and C statistic. RESULTS: 805 participants were included in the analysis. During 1-year of follow-up, 158 participants (20%) had died. Age, Charlson-Comorbidity-Index, number of drugs, body mass index, number of hospitalizations, Barthel-Index (functional impairment), and nursing home residency were predictors of 1-year mortality in a multivariable model. Using these variables, the 1-year probability of dying could be predicted with an optimism-corrected C statistic of 0.70. The optimism-corrected calibration slope was 0.93. Based on the derived point-based risk score to predict mortality risk, 7% of the patients classified at low-risk of mortality, 19% at moderate-risk, and 37% at high-risk died after one year of follow-up. A simpler mortality score, without the Charlson-Comorbidity-Index and Barthel-Index, showed reduced discriminative power (optimism-corrected C statistic: 0.59) compared to the full score. CONCLUSION: We developed and internally validated a mortality risk index including for the first-time specific predictors for multimorbid adults. This new 1-year mortality prediction point-based score allowed to classify multimorbid older patients into three categories of increasing risk of mortality. Further validation of the score among various populations of multimorbid patients is needed before its implementation into practice.
format Online
Article
Text
id pubmed-9355209
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-93552092022-08-06 Development and validation of a new prognostic index for mortality risk in multimorbid adults Gastens, Viktoria Chiolero, Arnaud Anker, Daniela Schneider, Claudio Feller, Martin Bauer, Douglas C. Rodondi, Nicolas Giovane, Cinzia Del PLoS One Research Article CONTEXT: Multimorbidity is highly prevalent among older adults and associated with a high mortality. Prediction of mortality in multimorbid people would be clinically useful but there is no mortality risk index designed for this population. Our objective was therefore to develop and internally validate a 1-year mortality prognostic index for older multimorbid adults. METHODS: We analysed data of the OPERAM cohort study in Bern, Switzerland, including 822 adults aged 70 years or more with multimorbidity (3 or more chronic medical conditions) and polypharmacy (use of 5 drugs or more for >30 days). Time to all-cause mortality was assessed up to 1 year of follow-up. We performed a parametric Weibull regression model with backward stepwise selection to identify mortality risk predictors. The model was internally validated and optimism corrected using bootstrapping techniques. We derived a point-based risk score from the regression coefficients. Calibration and discrimination were assessed by the calibration slope and C statistic. RESULTS: 805 participants were included in the analysis. During 1-year of follow-up, 158 participants (20%) had died. Age, Charlson-Comorbidity-Index, number of drugs, body mass index, number of hospitalizations, Barthel-Index (functional impairment), and nursing home residency were predictors of 1-year mortality in a multivariable model. Using these variables, the 1-year probability of dying could be predicted with an optimism-corrected C statistic of 0.70. The optimism-corrected calibration slope was 0.93. Based on the derived point-based risk score to predict mortality risk, 7% of the patients classified at low-risk of mortality, 19% at moderate-risk, and 37% at high-risk died after one year of follow-up. A simpler mortality score, without the Charlson-Comorbidity-Index and Barthel-Index, showed reduced discriminative power (optimism-corrected C statistic: 0.59) compared to the full score. CONCLUSION: We developed and internally validated a mortality risk index including for the first-time specific predictors for multimorbid adults. This new 1-year mortality prediction point-based score allowed to classify multimorbid older patients into three categories of increasing risk of mortality. Further validation of the score among various populations of multimorbid patients is needed before its implementation into practice. Public Library of Science 2022-08-05 /pmc/articles/PMC9355209/ /pubmed/35930547 http://dx.doi.org/10.1371/journal.pone.0271923 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Gastens, Viktoria
Chiolero, Arnaud
Anker, Daniela
Schneider, Claudio
Feller, Martin
Bauer, Douglas C.
Rodondi, Nicolas
Giovane, Cinzia Del
Development and validation of a new prognostic index for mortality risk in multimorbid adults
title Development and validation of a new prognostic index for mortality risk in multimorbid adults
title_full Development and validation of a new prognostic index for mortality risk in multimorbid adults
title_fullStr Development and validation of a new prognostic index for mortality risk in multimorbid adults
title_full_unstemmed Development and validation of a new prognostic index for mortality risk in multimorbid adults
title_short Development and validation of a new prognostic index for mortality risk in multimorbid adults
title_sort development and validation of a new prognostic index for mortality risk in multimorbid adults
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355209/
https://www.ncbi.nlm.nih.gov/pubmed/35930547
http://dx.doi.org/10.1371/journal.pone.0271923
work_keys_str_mv AT gastensviktoria developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults
AT chioleroarnaud developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults
AT ankerdaniela developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults
AT schneiderclaudio developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults
AT fellermartin developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults
AT bauerdouglasc developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults
AT rodondinicolas developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults
AT giovanecinziadel developmentandvalidationofanewprognosticindexformortalityriskinmultimorbidadults